Sign in
Not yet taking people in United StatesEarly phase 1

Gut bacteria mixture MITI-001 for irritable bowel syndrome with diarrhea

Tests the safety of MITI-001, a gut bacteria mixture, in adults with IBS-D.

Key facts

Who runs it
Stanford University
Where
Redwood City and Stanford, United StatesSee the 2 sites
Trial code
Registry title
Use of A Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea
Status
Not yet recruiting
Phase
Early phase 1
People taking part
13 people, planned
Started
Dec 2025
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • MITI-001 administration
Record updated
20 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with irritable bowel syndrome with diarrhea (IBS-D) who show signs of a gut bacteria problem. It tests the safety of MITI-001, a mix of live gut bacteria.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
IBS-D diagnosed by the Rome IV criteria. Normal C-reactive protein level. Gallbladder still in place.
Earlier treatment
No probiotic within one month before the first dose. No active antibiotic use, except antibiotics set by the protocol. No GI surgery below the stomach outlet (pylorus). People must be able to tolerate planned antibiotics, an upper endoscopy (EGD) and a colonoscopy with bowel cleansing.
Biomarker or test result
At least 1 of: primary bile acid proportion ≥ 12% in stool samples, or a positive hydrogen breath test (with glucose or lactulose).

Main reasons for not taking part

  • Inflammatory bowel disease, untreated gut infection or active bowel blockage
  • High bleeding risk, or use of blood thinners or antiplatelet drugs
  • Severe weakness of the immune system, including HIV, chemotherapy, steroids or radiation therapy
  • Kidney problems (estimated glomerular filtration rate < 50 mL/min)
  • Pregnant, breastfeeding or planning pregnancy during the study

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Age 18 to 65 years inclusive at the time of signing the informed consent
  • Diagnosis of IBS-D according to the Rome IV criteria (Lacy 2017)
  • At least 1 of the following measures of microbiome dysfunction:; Primary bile acid proportion ≥ 12% in stool samples, or; Positive hydrogen breath test (with either glucose or lactulose substrate) (Rezaie 2017)
  • Normal C-reactive protein level
  • Gallbladder intact
  • Willing to use appropriate contraception during the treatment period and for one week after the last study visit; Male participants with partners who are women of childbearing potential (WOCBP): Appropriate contraception includes condoms or other means considered adequate by the responsible Investigator; Female participants who are WOCBP: Appropriate contraception includes condoms, an intrauterine device, hormonal contraception, or other means considered adequate by the responsible Investigator
  • Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
  • Able to tolerate the planned course of antibiotics, EGD, and colonoscopy with bowel lavage

Who cannot take part

  • Severe immunodeficiency, inherited or acquired (e.g., human immunodeficiency virus, active chemotherapy or immunosuppressive medications [including steroids, biologic therapy, or bone marrow suppressive agent], or radiation therapy)
  • Active treatment with high levels of immunosuppressive therapies (active chemotherapy or immunosuppressive medications [including steroids, biologic therapies, or bone marrow suppressive agents], or radiation therapy)
  • Active anticoagulant or antiplatelet therapy, or use of other medications associated with a high risk of bleeding within 48 hours prior to endoscopy on Day 1
  • Use of a probiotic within one month prior to dosing of MITI-001 on Day 1
  • Inflammatory bowel disease
  • Untreated enteric infections
  • History of gastrointestinal (GI) surgery: All participants with GI surgeries below the pylorus will be excluded from this study. This includes participants with a history of colectomy, segmental colonic resection, and small bowel resections
  • History of recurrent aspiration episodes
  • Any conditions associated with a high risk of bleeding, including but not limited to coagulopathy/bleeding disorder, severe liver disease, active or recent GI bleeding, or recent abdominal or other GI surgery
  • Active diagnosis of major depressive disorder
  • Any other significant medical condition that could confound or interfere with evaluation of safety or tolerability or prevent compliance with the study protocol at the discretion of the Investigator
  • Renal insufficiency (estimated glomerular filtration rate < 50 mL/min)
  • Active drug or alcohol use disorder
  • Known allergy or anaphylaxis to vancomycin, metronidazole, ciprofloxacin, or polyethylene glycol
  • Absolute neutrophil count < 1000 μL, platelet count < 50 × 109/L, or hemoglobin level < 6.5 g/dL
  • Documented severe gastroparesis
  • Active intestinal obstruction
  • Dysphagia (oropharyngeal, esophageal, functional, or neuromuscular)
  • Active antibiotic use (except protocol-specified antibiotics)
  • Simultaneous participation in another interventional clinical trial
  • Pregnant, breastfeeding, or planning pregnancy during the study period
  • Inability to comply with research requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Stanford Digestive Health ClinicRedwood City, United StatesContact: Sean Assistant Professor of MedicineNot yet recruiting
  • Stanford UniversityStanford, United StatesContact: Sean Assistant Professor of MedicineNot yet recruiting

About the trial

What the trial wants to find out

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms.

Read full original descriptionShow less

MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

The group in the trial

  • Intervention arm (MITI-001)Treatment being tested

    Dosed with MITI-001

    Treatment: MITI-001 administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Study to Evaluate the Safety of a Complex Gut Bacterial Consortium (MITI 001) for the Treatment of Irritable Bowel Syndrome With Diarrhea
Plain-language title
Gut bacteria mixture MITI-001 for irritable bowel syndrome with diarrheaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07238790, who can take part
Record updated
20 November 2025